

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 12, 2018

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司* (the “**Company**”) announces that at the annual general meeting of the Company held on June 12, 2018 (the “**AGM**”), all proposed resolutions as set out in the notice of the AGM dated April 26, 2018 were duly passed by the shareholders of the Company by way of poll.

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and of the independent auditors of the Company for the year ended December 31, 2017.	999,723,561 (99.99%)	820 (0.01%)
2.	(a) To re-elect Dr. Ge Li as non-executive director.	993,432,764 (99.37%)	6,266,617 (0.63%)
	(b) To re-elect Dr. Zhisheng Chen as executive director.	997,088,381 (99.72%)	2,750,000 (0.28%)
	(c) To re-elect Dr. Weichang Zhou as executive director.	995,654,381 (99.58%)	4,184,000 (0.42%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
	(d) To re-elect Mr. Edward Hu as non-executive director.	994,083,687 (99.42%)	5,754,694 (0.58%)
	(e) To re-elect Mr. Yibing Wu as non-executive director.	995,345,359 (99.55%)	4,493,022 (0.45%)
	(f) To re-elect Mr. Yanling Cao as non-executive director.	995,345,359 (99.55%)	4,493,022 (0.45%)
	(g) To re-elect Mr. William Robert Keller as independent non-executive director.	998,175,044 (99.83%)	1,663,337 (0.17%)
	(h) To re-elect Mr. Teh-Ming Walter Kwauk as independent non-executive director.	996,944,044 (99.71%)	2,894,337 (0.29%)
	(i) To re-elect Mr. Wo Felix Fong as independent non-executive director.	905,445,404 (90.59%)	94,084,477 (9.41%)
3.	To authorise the board of Directors or any duly authorised board committee to fix the Directors' remuneration.	996,438,881 (99.98%)	173,000 (0.02%)
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorise the board of Directors or any duly authorised board committee to fix their remuneration.	998,751,881 (99.89%)	1,086,500 (0.11%)
5.	To grant a general mandate to the Directors to issue, allot and deal with the shares of the Company.	778,639,847 (77.91%)	220,756,534 (22.09%)
6.	To grant a general mandate to the Directors to repurchase the shares of the Company.	999,382,561 (99.99%)	13,820 (0.01%)
7.	To extend the general mandate granted to the Directors to issue the shares of the Company by adding thereto the shares to be repurchased by the Company.	790,678,627 (79.10%)	208,970,487 (20.90%)

As at the date of the AGM, the total number of shares of the Company in issue, being the total number of shares entitling the holders thereof to attend and vote on any of the resolutions proposed at the AGM, was 1,224,509,752 shares. There were no restrictions on any shareholders of the Company to cast votes on any of the resolutions proposed at the AGM. No shareholder of the Company has stated his/her/its intention in the Company's circular dated April 26, 2018 to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company's share registrar in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

For and on behalf of the Board
WuXi Biologics (Cayman) Inc.
藥明生物技術有限公司*
Dr. Ge Li
Chairman

Hong Kong, June 12, 2018

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

** For identification purpose only*